What kind of company is Syneos Health?
SYNEOS HEALTH, INC. : SYNH Stock Price | US87166B1026 | MarketScreener SYNEOS HEALTH, INC. Syneos Health, Inc. is a biopharmaceutical solutions company. It provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries.
Is Syneos stock still a buy at $79?
Since the turn of the year, however, Syneos stock has been sliding, falling to a value of $79 at the time of writing, and meaning that the overall share price gain over the past 12 months is just +5%.
Is Syneos'debt too much of a strain on investors?
Icon also reported current assets of $1.8bn as of Q421, so although not great news for investors, Syneos' debt ought not to be too much of a strain on its drive for greater profitability in the long run.
Is Syneos’ financial leverage a threat to the CRO industry?
High financial leverage could constrain the company’s ability to compete against other top CROs by limiting capital allocation. Syneos could fall behind in innovation as technology and data play an increasing role in the CRO industry.
Is Syneos publicly traded?
The stock of Syneos Health is traded under the symbol “SYNH” on the Nasdaq Global Select Market. The company's common stock can be bought or sold through a stock broker, bank or any financial institution that provides brokerage services.
Who did Syneos merger with?
inVentiv HealthSyneos Health was formed in 2017 via a merger between 2 Contract Research Organizations, INC Research and inVentiv Health. From a share price perspective progress was slow initially, before the stock price gained 98% between late 2020 - late 2021.
What does Syneos Health sell?
Our customers span the spectrum of healthcare from blockbusters to niche products; large biopharmaceutical to emerging specialty companies; biotechnology to devices and diagnostics; healthcare technology, hospitals, non-profits and academic centers.
Who are Syneos Health competitors?
Syneos Health's top competitors include ICON, PPD, Worldwide Clinical Trials, IQVIA, PRA Health Sciences and Parexel International.
Is Syneos health for sale?
Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the Selling Stockholders in the Offering. The Offering is expected to close on May 6, 2021, subject to customary closing conditions.
When did Syneos go public?
The shares sold in the IPO began trading on the NASDAQ Global Select Market under the symbol "INCR" on Nov. 7, 2014 .
Is Syneos Health a good company?
Great place to work, very flexible Syneos is a pretty big company but the team I work with is awesome. I've gotten the support I need from my managers, work from home and I have the flexibility I need. As long as work is done and meetings and deadlines met there is no issues.
Is Syneos a Fortune 500 company?
Syneos Health | 2022 Fortune 500 | Fortune.
Does Syneos Health pay well?
The average Syneos Health salary ranges from approximately $43,388 per year for Director of Public Relations to $177,619 per year for Senior Director. Average Syneos Health hourly pay ranges from approximately $14.97 per hour for Receptionist to $91.87 per hour for Senior Executive Coordinator.
How big is Syneos health?
Syneos HealthTypePublicArea servedWorldwideKey peopleMichelle Keefe (CEO)RevenueUS$4.676 billion (2019)Number of employees28,000 (2022)8 more rows
Which is better Iqvia or Syneos?
IQVIA is most highly rated for Work/life balance and Syneos Health is most highly rated for Work/life balance....Overall Rating.Overall Rating3.83.6Compensation and benefits3.53.5Job security and advancement3.33.0Management3.43.2Culture3.63.41 more row
How many employees does Syneos have?
approximately 28,000 employeesDiscover what our approximately 28,000 employees already know: Syneos Health® is an exciting place to be.
Should I buy or sell Syneos Health stock right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 ho...
What is Syneos Health's stock price forecast for 2022?
9 analysts have issued twelve-month price targets for Syneos Health's shares. Their forecasts range from $75.00 to $122.00. On average, they expect...
How has Syneos Health's stock performed in 2022?
Syneos Health's stock was trading at $102.68 at the start of the year. Since then, SYNH stock has decreased by 33.9% and is now trading at $67.90....
Are investors shorting Syneos Health?
Syneos Health saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 1,910,000 shares, a decre...
When is Syneos Health's next earnings date?
Syneos Health is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Syneos H...
How were Syneos Health's earnings last quarter?
Syneos Health, Inc. (NASDAQ:SYNH) posted its quarterly earnings results on Friday, April, 29th. The company reported $1.01 earnings per share for t...
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $5.05-$5.25 for the perio...
Who are Syneos Health's key executives?
Syneos Health's management team includes the following people: Ms. Michelle Keefe , CEO & Director (Age 55, Pay $580.7k) ( LinkedIn Profile ) Mr...
What is Alistair Macdonald's approval rating as Syneos Health's CEO?
322 employees have rated Syneos Health CEO Alistair Macdonald on Glassdoor.com . Alistair Macdonald has an approval rating of 82% among Syneos Hea...
What is MarketBeat community ratings?
What is the P/E ratio of Syneos Health?
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote “Outperform” if you believe SYNH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
How much is Syneos Health's 2021 earnings?
The P/E ratio of Syneos Health is 41.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.35.
How much does Syneos Health make?
Syneos Health updated its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share guidance of $4.350-$4.490 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.350. The company issued revenue guidance of $5.20 billion-$5.28 billion, compared to the consensus revenue estimate of $5.25 billion.
What is Syneos Health?
Syneos Health has a market capitalization of $9.15 billion and generates $4.42 billion in revenue each year. The company earns $192.79 million in net income (profit) each year or $2.85 on an earnings per share basis.
What is the NASDAQ symbol for Syneos?
Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.
When will Syneos Health release its earnings?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
Transparency is our policy. Learn how it impacts everything we do
Syneos Health is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Syneos Health.
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
